Symbols

ADAP(Delisted)

Adaptimmune·NASDAQ

--(--)

Signals Analysis

Bullish signal 0

Bearish signal 3

Significant Revenue Decline

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ADAP

Adaptimmune Therapeutics Plc

A leader in cell therapy to treat cancer

Industry

Established Date

12/03/2014

Listing Date

05/06/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

506

Fiscal Year Ends

12-31

Website

www.adaptimmune.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

60 Jubilee Avenue, Milton Park, Abingdon, OxfordshireOX14 4RX, United Kingdom

Business

Introduction

Adaptimmune Therapeutics Plc was established on 3 December 2014 and is a public limited company incorporated under the laws of England and Wales. The company is a clinical-stage biopharmaceutical company that will transition to a commercial-stage cell therapy company in 2024. The company focuses on providing novel cell therapies to cancer patients. The company's first product, afamitresgene autoleucel or "afami-cel", is unique to synovial sarcoma and will be the first product in the sarcoma product franchise. The Lete-cel, which they plan to launch commercially in the US in 2026, will be the second product in the sarcoma franchise and will target both synovial sarcoma and myxoid round cell liposarcoma, significantly expanding the treatable patient population.

Earnings Call

Q1/2025

Estimate EPS-0.17

Actual EPS-0.03

Estimate Revenue6.55M

Actual Revenue7.29M

Adaptimmune's Q1 2025: Key Contradictions in Apheresis Pace, Manufacturing Capacity, and Patient Incidence

May 20,2025 11:31·
Earnings Decrypt

Company Financials

EPS

ADAP has released its 2025 Q2 earnings. EPS was reported at -0.02, versus the expected -0.13, beating expectations. The chart below visualizes how ADAP has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ADAP has released its 2025 Q2 earnings report, with revenue of 13.68M, reflecting a YoY change of -89.33%, and net profit of -30.34M, showing a YoY change of -143.64%. The Sankey diagram below clearly presents ADAP's revenue sources and cost distribution.